China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Set to Reverse Split on Tuesday, February 3rd

Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) are going to reverse split before the market opens on Tuesday, February 3rd. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, February 2nd.

China SXT Pharmaceuticals Stock Down 38.0%

Shares of SXTC traded down $0.02 on Friday, hitting $0.03. The company’s stock had a trading volume of 64,536,454 shares, compared to its average volume of 36,097,512. China SXT Pharmaceuticals has a fifty-two week low of $0.03 and a fifty-two week high of $7.84. The company has a 50 day moving average price of $1.05 and a 200 day moving average price of $1.37.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its quarterly earnings data on Wednesday, December 31st. The company reported ($0.03) EPS for the quarter. The business had revenue of $0.31 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in China SXT Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 48,759 shares of the company’s stock, valued at approximately $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.